Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Not yet recruiting 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Nasopharyngeal Carcinoma 7Esophageal Squamous Cell Carcinoma 4Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Non-Small-Cell Lung 3Advanced Solid Tumor 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Nasopharyngeal Neoplasms 2Head and Neck Neoplasms 2Breast Neoplasms 2Advanced Breast Cancer 2Urinary Bladder Neoplasms 1Turcot syndrome 1Solid Tumor 1Skin Neoplasms 1Sarcoma 1Recurrence 1Papillomavirus Infections 1Pancreatic Cancer Metastatic 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Muscle Invasive Bladder Cancer (MIBC) 1Mouth Neoplasms 1Meningeal Carcinomatosis 1Locally Advanced or Metastatic GC and GCJ Adenocarcinoma 1

Interventions

Carboplatin 121pembrolizumab 119Pemetrexed 102Cisplatin 76Paclitaxel 56osimertinib 52Nivolumab 50Docetaxel 50durvalumab 47Specimen Handling 37Gemcitabine 34Magnetic Resonance Spectroscopy 33Radiosurgery 27Cetuximab 26130-nm albumin-bound paclitaxel 26atezolizumab 25Radiotherapy 20Ipilimumab 19Drug Therapy 19Bevacizumab 19cemiplimab 17amivantamab 17Taxes 16Ramucirumab 13alectinib 12tislelizumab 11lazertinib 11Leucovorin 11Fluorouracil 11Radiation 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × toripalimab × 90 days × Clear all
NCT06437977 2026-05-13

neoR-TORCH

Shanghai Chest Hospital

Phase 3 Recruiting
478 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06706219 2026-04-03

Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC

Hunan Province Tumor Hospital

Phase 2 Not yet recruiting
50 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07493980 2026-03-27

Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2 Not yet recruiting
54 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡